Clinical development failure
The lead therapeutic and vaccine programs are still in early stages and may not produce statistically significant or commercially viable results.
- Scope
- lira-cel and cancer vaccine pipeline
- Materiality
- high
Anixa Biosciences Inc
Anixa Biosciences Inc. is a U.S.-based biotechnology company focused on developing cancer therapies and vaccines for areas of high unmet medical need. Its lead therapeutic program is liraltagene autoleucel (lira-cel), a CAR-T-based approach being developed for ovarian cancer through its subsidiary Certainty Therapeutics. The company also has vaccine programs targeting breast cancer and ovarian cancer, plus an early discovery platform aimed at additional cancers such as lung, colon, and prostate. Anixa is still in the research and clinical development stage and has not yet generated revenue from its core oncology programs.
8.08
8.08
| % | |
|---|---|
| Cell therapy therapeutics | 0% Development of lira-cel, a CAR-T-based therapeutic for ovarian cancer. |
| Cancer vaccines | 0% Vaccine programs focused on breast cancer, ovarian cancer, and other solid tumors. |
| Discovery-stage oncology platform | 0% Early-stage research to identify additional cancer vaccine candidates for high-incidence cancers. |
| Legacy intellectual property licensing | 100% Limited patent licensing and sale of patented technologies from older operations. |
Anixa does not currently sell approved oncology products, so its direct customer base is not yet established in the...
- Cancer treatment providersprimary
Hospitals, oncology clinics, and cancer centers that would use approved therapies or vaccines in clinical practice.
- Patients with unmet oncology needsprimary
Patients with ovarian, breast, and other hard-to-treat cancers who would be the end beneficiaries of the products.
- Pharmaceutical licensing partnersprimary
Large drug companies that may license, manufacture, and commercialize Anixa's technologies.
- Intellectual property licenseessecondary
Counterparties in legacy technology licensing and patent sale transactions.
Anixa is headquartered in the United States and its business is primarily U.S.-centric from a research, clinical, and...
- •Headquartered in the United States
- •Clinical and research collaborations with U.S. institutions such as Moffitt and Cleveland Clinic
- •No meaningful current revenue geography because core programs are pre-revenue
- •Future commercialization would likely depend on U.S. and global regulatory approvals
- •Legacy licensing activity is limited and not a material geographic driver
Anixa’s strategy is to advance a small number of oncology programs while conserving capital through external...
01
Advance oncology pipeline through clinical and preclinical developmentshort-term
Clinical data and regulatory progress are required before the company can create commercial value or attract licensing partners.
02
Partner for manufacturing and commercializationmedium-term
The company lacks the scale to build a full commercial organization and depends on partners to reach market efficiently.
03
Preserve liquidity and access to capitalshort-term
As a pre-revenue biotech, continued development depends on external funding and disciplined cash management.
The company faces the classic risks of an early-stage biotech: no product revenue, uncertain clinical outcomes, and a...
Funding and dilution risk
The company has a history of losses and may need additional capital to continue development.
- Scope
- equity offerings, ATM program, potential debt financing
- Materiality
- high
Partner dependence
Anixa relies on collaborators and subcontractors for trials, manufacturing, and eventual commercialization.
- Scope
- research institutions, manufacturing partners, pharma licensees
- Materiality
- high
Competitive displacement
Larger companies may develop safer, more effective, or faster-approved oncology products.
- Scope
- CAR-T and cancer vaccine markets
- Materiality
- medium
Regulatory and market acceptance risk
Even if approved, products may not gain physician, payer, or patient adoption.
- Scope
- future oncology commercialization
- Materiality
- medium
Revenue recognition for IP licensing
Can shift revenue recognition between periods and affect comparability
Research and development expense allocation
Drives reported operating loss and can create quarter-to-quarter volatility
Stock-based compensation
Affects non-cash operating expense and net loss
ALX ONCOLOGY HOLDINGS INC
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Immix Biopharma, Inc.
IMMX · Pharmaceutical Preparations
Candel Therapeutics, Inc.
CADL · Biological Products, (No Diagnostic Substances)
Annexon, Inc.
ANNX · Pharmaceutical Preparations
Ernexa Therapeutics Inc.
ERNA · Pharmaceutical Preparations
: 11/08/2026